Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A French Observational Longitudinal Multicenter Study of Adult Patients Treated in the Real-life Setting With Olaparib for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT06031805 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06031805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06031805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A French Observational Longitudinal Multicenter Study of Adult Patients Treated in the Real-life Setting With Olaparib for the Treatment of Metastatic Castration Resistant Prostate Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
October 11, 2023
Completion date
October 13, 2028
Enrollment
159 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer